Agilent Technologies Inc. (NYSE:A) shares are up during Monday’s premarket session as the company announces the acquisition of Biocare Medical for around $950 million.

Synergies

Biocare Medical has been a prominent player in the pathology space, offering a range of immunohistochemistry and hybridization solutions.

Biocare has over 300 specialized antibodies and robust R&D capabilities.

It has consistently achieved double-digit revenue and profit growth since 2021, making it a valuable addition to Agilent’s offerings.

The addition of Biocare’s IHC antibodies, reagents, and instrument portfolio strengthens Agilent’s immunohistochemistry offering and broadens its reach across clinical and research pathology labs.

Agilent expects Biocare’s strong growth in the IHC market and its efficient product innovation capabilities to enhance it’s ability to develop and commercialize new IVD antibodies.

The deal is expected to be completed by Agilent’s fourth fiscal quarter of 2026, subject to customary closing conditions, including regulatory approvals.

Once finalized, Biocare will be integrated into Agilent’s Life Sciences and Diagnostics Markets Group.

The transaction is expected to boost Agilent’s revenue growth, margins, and non-instrument revenue mix in its first year.

It is also projected to become accretive to EPS roughly 12 months after closing.

As of January 31, 2026, Agilent’s cash and cash equivalents ...